Brokers Offer Predictions for Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at Chardan Capital issued their FY2025 earnings estimates for Prothena in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li expects that the biotechnology company will post earnings of ($3.25) per share for the year. Chardan Capital currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Several other equities research analysts have also commented on PRTA. Piper Sandler boosted their target price on shares of Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Oppenheimer boosted their price target on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. Finally, Bank of America lowered their price target on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Prothena has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Prothena Price Performance

Shares of PRTA stock opened at $13.14 on Thursday. The business’s fifty day moving average price is $14.32 and its 200 day moving average price is $15.61. The firm has a market capitalization of $707.29 million, a PE ratio of -5.71 and a beta of -0.02. Prothena has a 1-year low of $11.70 and a 1-year high of $26.36.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The business had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC increased its position in Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after buying an additional 833 shares in the last quarter. Headlands Technologies LLC boosted its stake in shares of Prothena by 196.5% during the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 4,858 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Prothena during the 4th quarter worth about $145,000. Purkiss Capital Advisors LLC acquired a new position in Prothena in the 4th quarter valued at about $149,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,065 shares in the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.